ウイルス増感剤の世界市場

ウイルス増感剤の世界市場は2030年までに39億米ドルに達する

2024年に20億米ドルと推定されるウイルス増感剤の世界市場は、分析期間2024-2030年にCAGR 12.3%で成長し、2030年には39億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗ウイルス薬開発アプリケーションは、CAGR 10.9%を記録し、分析期間終了時には21億米ドルに達すると予測されます。ワクチン開発アプリケーション分野の成長率は、分析期間中CAGR13.6％と推定されます。

米国市場は5億3,660万米ドルと推定、中国はCAGR16.3％で成長予測

米国のウイルス増感剤市場は、2024年に5億3,660万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億1,860万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは16.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.1%と10.8%と予測されています。欧州では、ドイツがCAGR約9.7%で成長すると予測されています。

世界のウイルス増感剤市場- 主要動向と促進要因まとめ

ウイルス増感剤とは何か、なぜ現代の生物医学調査で注目されているのか？

ウイルス増感剤とは、ウイルス感染に対する宿主細胞の感受性を高めたり、標的治療におけるウイルス複製の効力を高めたりする化合物や薬剤のことです。従来、ウイルス学の目的は感染を予防することでしたが、ウイルス増感剤は、ウイルス遺伝子治療、腫瘍溶解性ウイルス治療、ワクチン開発などの治療戦略における役割で注目されています。このような状況では、特定の細胞や組織をウイルスベクターに感作することで、治療の効率や精度を向上させることができます。例えば、がん細胞に選択的に感染し破壊するようにウイルスを設計する腫瘍溶解性ウイルス療法では、増感剤を用いて悪性細胞へのウイルス侵入を促進する一方、健康な組織は温存します。この標的アプローチは、薬剤耐性や腫瘍の不均一性に伴う限界を克服する可能性があります。ワクチン開発において、ある種の増感剤は、ウイルスの取り込みと抗原提示をより確実にすることにより、免疫反応を増幅するのに役立ちます。その他の特典として、インターフェロン応答などの細胞防御機構を克服し、治療効果を高めるためにウイルスの複製を最適化する役割を果たす化合物の研究が進んでいます。バイオテクノロジーの進歩に伴い、これらの化合物は、より高い特異性、より低い毒性、多様なウイルスプラットフォームとの適合性を目指して設計されています。治療領域全体にわたって拡大するその役割は、より効果的で細胞特異的な治療を求める製薬会社や研究機関の関心を集めており、ウイルス増感剤は将来の医療介入の重要な要素となっています。

技術の進歩はウイルス増感剤の開発と応用をどのように変えていますか？

分子生物学、遺伝子工学、ナノテクノロジーの急速な進歩は、より洗練されたウイルス増感剤の開発に大きな影響を与えています。CRISPRベースの遺伝子編集やハイスループットスクリーニングのような最新の研究ツールにより、ウイルスの侵入、複製、排出を制御する宿主細胞因子の同定と検証が可能になりました。これらの発見により、特定の細胞経路を調節してウイルス受容体をアップレギュレートしたり、抗ウイルス防御を一時的に抑制したりすることで、ウイルスに基づく治療法の性能を向上させる増感剤の設計が可能になりつつあります。また、ナノ粒子送達システムの進歩により、増感剤を疾患部位に直接輸送することが可能になり、全身への曝露や潜在的な標的外影響を最小限に抑えることができます。これと並行して、バイオインフォマティクスと機械学習ツールは、細胞-ウイルス相互作用を予測し、安全性プロファイルを改善した新しい増感剤の候補を同定するために用いられています。研究者はまた、特に攻撃性の強いがんや遺伝性疾患の治療において、相乗効果を得るために増感剤をウイルスベクターと併用投与する併用療法を模索しています。さらに、合成生物学は、環境的な合図や特定の細胞マーカーに反応するウイルスベクターや増感剤の設計において、極めて重要な役割を果たしています。これらの技術革新は、ウイルス増感剤を実験的試薬から洗練された治療ツールへと変貌させ、その適用範囲を広げ、臨床への統合を改善しつつあります。ウイルス増感剤は、より正確でカスタマイズ可能なツールとなり、先進的なバイオメディカルアプリケーションにおけるウイルス増感剤の役割は大きく成長すると期待されています。

なぜウイルス増感剤は、がんや遺伝子治療の進化に不可欠なのでしょうか？

医療界がより個別化され、ターゲットを絞った治療法へとシフトし続ける中、ウイルス増感剤はがんや遺伝子治療の進歩に不可欠な要素として浮上しています。腫瘍学において、がん細胞を破壊するためのがん溶解ウイルスの使用は、腫瘍組織内に選択的に浸潤し複製するウイルスの能力に大きく依存しています。しかし、多くの腫瘍はウイルスの侵入や複製を阻止する本質的な耐性機構を持っています。増感剤は、宿主の抗ウイルスタンパク質をダウンレギュレートするか、あるいはがん細胞表面のウイルスレセプターをアップレギュレートすることによって、これらのメカニズムを調節するために使用されます。これにより、ウイルス剤の治療指数が向上し、より効率的な腫瘍ターゲティングが可能となります。精度が重要な遺伝子治療の分野では、増感剤は神経細胞、筋繊維、造血幹細胞などの形質導入が困難な細胞へのウイルスベクターの導入を容易にします。さらに、増感剤は細胞環境を一過性に変化させるように微調整することができ、正常な細胞機能を長期にわたって破壊することなく、最適なベクター活性を得ることができます。ウイルスが体内で作用する場所とタイミングをコントロールできることは、副作用を最小限に抑え、治療成績を向上させる上で大きな利点となります。さらに、研究者たちは現在、感作剤と免疫調節剤の両方の働きをする二重機能剤を研究しており、それによってウイルスの効力と宿主の免疫応答の両方を高めています。このような開発は、特に高度に的を絞った介入を必要とする複雑な疾患において、次世代治療アプローチで直面する主な限界を克服する上で、ウイルス増感剤が中心的な役割を果たすことを強調しています。

ウイルス増感剤への世界の関心と市場成長の原動力は？

ウイルス増感剤市場の成長は、バイオテクノロジーの進化、アンメットクリニカルニーズ、ウイルス療法研究の増加と密接に関連したいくつかの要因によって牽引されています。特に、従来の治療法では成功が限られていたがんや遺伝性疾患の治療において、標的を絞った個別化医療に対する需要が高まっていることが、最も強力な原動力の一つです。ウイルスベースの治療薬が規制当局の承認を得て商業的な牽引力を持つにつれ、その性能を高める補完的な薬剤の必要性が高まっています。もう一つの重要な要因は、遺伝子治療や細胞治療のパイプラインに対する製薬会社やバイオテクノロジー企業の投資が急増していることです。これらの企業は、ベクターの効率、組織選択性、安全性を向上させる技術革新を積極的に求めており、これらはすべて増感剤の使用によってサポートされます。さらに、オンコリティックウイルス療法と免疫ウイルス療法が実行可能な治療選択肢として受け入れられつつあることから、腫瘍微小環境の調節と耐性克服における増感剤の役割に注目が集まっています。また、臨床試験デザインと規制経路の開発により、これらの補助技術の迅速な開発と承認が可能になりつつあります。政府が資金を提供する研究イニシアティブや学術機関と業界関係者のコラボレーションは、技術革新をさらに促進し、ウイルス増感剤の潜在的応用を拡大しています。ウイルスの病原性や宿主細胞の生物学的性質に対する理解が深まるにつれ、治療効果を得るためにこれらの相互作用を操作する新たな機会が生まれています。これらの動向により、ウイルス増感剤は、臨床研究、医薬品開発、将来のヘルスケア戦略において重要性を増す、幅広いバイオメディカル市場において将来性の高いセグメントとして確立されつつあります。

セグメント

用途（抗ウイルス薬開発、ワクチン開発、がん細胞ウイルス治療）、最終用途（製薬企業、バイオテクノロジー企業、研究開発、その他最終用途）

調査対象企業の例

• AbbVie
• ALSTEM
• Alnylam Pharmaceuticals
• AstraZeneca
• Bluebird Bio
• Bristol-Myers Squibb
• Cellectis
• Gilead Sciences
• Iovance Biotherapeutics
• Johnson & Johnson
• Merck & Co.
• Moderna
• Pfizer
• Regeneron Pharmaceuticals
• Roche（F. Hoffmann-La Roche）
• Takara Bio
• Thermo Fisher Scientific
• Virica Biotech
• Virongy Biosciences
• FUJIFILM Irvine Scientific

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Viral Sensitizers Market to Reach US$3.9 Billion by 2030

The global market for Viral Sensitizers estimated at US$2.0 Billion in the year 2024, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2024-2030. Antiviral Drug Development Application, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Vaccine Development Application segment is estimated at 13.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$536.6 Million While China is Forecast to Grow at 16.3% CAGR

The Viral Sensitizers market in the U.S. is estimated at US$536.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$818.6 Million by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Global Viral Sensitizers Market - Key Trends & Drivers Summarized

What Are Viral Sensitizers and Why Are They Gaining Attention in Modern Biomedical Research?

Viral sensitizers are compounds or agents that enhance a host cell’s susceptibility to viral infection or increase the efficacy of viral replication in targeted therapies. While traditionally, the objective in virology has been to prevent infection, viral sensitizers are gaining attention for their role in therapeutic strategies such as viral gene therapy, oncolytic virotherapy, and vaccine development. In these contexts, sensitizing specific cells or tissues to viral vectors can improve the efficiency and precision of treatment delivery. For instance, in oncolytic virotherapy, where viruses are engineered to selectively infect and destroy cancer cells, sensitizers are used to enhance viral entry into malignant cells while sparing healthy tissues. This targeted approach has the potential to overcome limitations associated with drug resistance and tumor heterogeneity. In vaccine development, certain sensitizing agents help amplify the immune response by ensuring better viral uptake and antigen presentation. Additionally, viral sensitizers are increasingly being studied for their role in overcoming cellular defense mechanisms such as interferon responses, thereby optimizing viral replication for therapeutic benefit. As biotechnology advances, these compounds are being engineered for higher specificity, lower toxicity, and compatibility with diverse viral platforms. Their expanding role across therapeutic areas is attracting the interest of pharmaceutical companies and research institutions seeking more effective, cell-specific treatments, positioning viral sensitizers as a critical component of future medical interventions.

How Are Technological Advancements Reshaping the Development and Application of Viral Sensitizers?

The rapid progress in molecular biology, genetic engineering, and nanotechnology is significantly influencing the development of more sophisticated viral sensitizers. Modern research tools such as CRISPR-based gene editing and high-throughput screening have made it possible to identify and validate host cell factors that regulate viral entry, replication, and egress. These discoveries are leading to the design of sensitizers that can modulate specific cellular pathways to either upregulate viral receptors or temporarily suppress antiviral defenses, thereby enhancing the performance of viral-based therapies. Advances in nanoparticle delivery systems are also enabling the targeted transport of sensitizers directly to disease sites, minimizing systemic exposure and potential off-target effects. In parallel, bioinformatics and machine learning tools are being employed to predict cell-virus interactions and identify new sensitizer candidates with improved safety profiles. Researchers are also exploring combination therapies where sensitizers are co-administered with viral vectors to achieve synergistic effects, particularly in the treatment of aggressive cancers and genetic disorders. Additionally, synthetic biology is playing a pivotal role in designing viral vectors and sensitizers that can respond to environmental cues or specific cellular markers. These technological innovations are transforming viral sensitizers from experimental reagents into refined therapeutic tools, broadening their applicability and improving their integration into clinical practice. As these tools become more precise and customizable, the role of viral sensitizers in advanced biomedical applications is expected to grow significantly.

Why Are Viral Sensitizers Crucial in the Evolving Landscape of Cancer and Gene Therapies?

As the medical community continues to shift toward more personalized and targeted treatment modalities, viral sensitizers are emerging as essential components in the advancement of cancer and gene therapies. In oncology, the use of oncolytic viruses to destroy cancer cells relies heavily on the ability of these viruses to infiltrate and replicate selectively within tumor tissues. However, many tumors possess intrinsic resistance mechanisms that prevent viral entry or replication. Sensitizers are employed to modulate these mechanisms, either by downregulating host antiviral proteins or by upregulating viral receptors on the surface of cancer cells. This enhances the therapeutic index of the viral agent and allows for more efficient tumor targeting. In the field of gene therapy, where precision is critical, sensitizers can facilitate the delivery of viral vectors into difficult-to-transduce cells such as neurons, muscle fibers, or hematopoietic stem cells. Moreover, sensitizers can be fine-tuned to transiently alter the cellular environment, allowing optimal vector activity without long-term disruption of normal cellular functions. The ability to control where and when viruses act within the body offers a major advantage in minimizing side effects and enhancing treatment outcomes. Additionally, researchers are now exploring dual-function agents that act both as sensitizers and immune modulators, thereby boosting both viral efficacy and host immune responses. These developments underscore the central role of viral sensitizers in overcoming some of the key limitations faced in next-generation therapeutic approaches, particularly in complex diseases that require highly targeted intervention.

What Is Driving the Global Interest and Market Growth for Viral Sensitizers?

The growth in the viral sensitizers market is driven by several factors closely linked to the evolution of biotechnology, unmet clinical needs, and increased research into viral therapies. One of the strongest drivers is the rising demand for targeted and personalized medicine, particularly in the treatment of cancers and genetic disorders where conventional therapies have limited success. As viral-based therapeutics gain regulatory approval and commercial traction, the need for complementary agents that can enhance their performance has become more pressing. Another important factor is the surge in investment from pharmaceutical and biotech companies in gene and cell therapy pipelines, many of which rely on viral vectors for delivery. These companies are actively seeking innovations that improve vector efficiency, tissue selectivity, and safety, all of which can be supported by the use of sensitizers. Additionally, the growing acceptance of oncolytic virotherapy and immunovirotherapy as viable treatment options has brought attention to the role of sensitizers in modulating tumor microenvironments and overcoming resistance. Advancements in clinical trial design and regulatory pathways are also enabling faster development and approval of these adjunctive technologies. Government-funded research initiatives and collaborations between academic institutions and industry players are further fueling innovation and expanding the potential applications of viral sensitizers. The increasing understanding of viral pathogenesis and host cell biology is creating new opportunities to manipulate these interactions for therapeutic gain. Together, these trends are establishing viral sensitizers as a high-potential segment within the broader biomedical market, with growing importance in clinical research, drug development, and future healthcare strategies.

SCOPE OF STUDY:

The report analyzes the Viral Sensitizers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Antiviral Drug Development Application, Vaccine Development Application, Oncolytic Viral Therapies Application); End-Use (Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie
• ALSTEM
• Alnylam Pharmaceuticals
• AstraZeneca
• Bluebird Bio
• Bristol-Myers Squibb
• Cellectis
• Gilead Sciences
• Iovance Biotherapeutics
• Johnson & Johnson
• Merck & Co.
• Moderna
• Pfizer
• Regeneron Pharmaceuticals
• Roche (F. Hoffmann-La Roche)
• Takara Bio
• Thermo Fisher Scientific
• Virica Biotech
• Virongy Biosciences
• FUJIFILM Irvine Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Viral Sensitizers - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Breakthroughs in Immunotherapy Throw the Spotlight on the Role of Viral Sensitizers in Cancer Treatment
  • Rising Investment in Virology Research Accelerates Demand for Targeted Sensitizing Agents
  • Expansion of mRNA and Viral Vector Platforms Strengthens the Case for Optimized Viral Sensitizers
  • Push Toward Personalized Medicine Enhances the Need for Precision Viral Sensitization Mechanisms
  • Adoption of Combination Therapies Drives Integration of Viral Sensitizers in Antiviral and Immunomodulatory Regimens
  • Increased Prevalence of Viral-Oncogenic Diseases Expands the Addressable Market for Therapeutic Sensitizers
  • Here's How Advancements in Viral Imaging and Biomarker Discovery Are Unlocking New Use Cases
  • Demand for Adjuvant Technologies in Vaccinology Bolsters Interest in Immune-Sensitizing Agents
  • Improved Understanding of Host-Virus Interactions Drives Development of Mechanistically Sophisticated Sensitizers
  • Shifting Focus Toward Immune Priming in Early Infection Stages Opens Strategic Demand for Prophylactic Sensitizers
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Viral Sensitizers Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Viral Sensitizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Viral Sensitizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Viral Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antiviral Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antiviral Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Antiviral Drug Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Vaccine Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Vaccine Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Vaccine Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Oncolytic Viral Therapies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Oncolytic Viral Therapies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Oncolytic Viral Therapies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceuticals Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Pharmaceuticals Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Pharmaceuticals Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: China 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Viral Sensitizers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Viral Sensitizers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Viral Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: France 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Viral Sensitizers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Viral Sensitizers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Viral Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 116: India Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: India 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 119: India Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: India 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Viral Sensitizers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Viral Sensitizers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Viral Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Viral Sensitizers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Viral Sensitizers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Viral Sensitizers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Viral Sensitizers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Viral Sensitizers by Application - Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Viral Sensitizers by Application - Percentage Breakdown of Value Sales for Antiviral Drug Development Application, Vaccine Development Application and Oncolytic Viral Therapies Application for the Years 2014, 2025 & 2030
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Viral Sensitizers by End-Use - Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Viral Sensitizers by End-Use - Percentage Breakdown of Value Sales for Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION